Chronic graft-versus-host disease: Is there an alternative to the conventional treatment?

Bone Marrow Transplantation

Volumn 25, Issue 7, 2000, Pages 689-696

  Gaziev, D ^a   Galimberti, M ^a   Lucarelli, G ^a   Polchi, P ^a  

^a SAN SALVATORE HOSPITAL   (Italy)

Author keywords

Bone marrow transplantation; Chronic GVHD; Treatment

Indexed keywords

ANTIESTROGEN; BILE ACID; CHELATING AGENT; CLOFAZIMINE; CYCLOFENIL; ETRETINATE; HALOFUGINONE; HISTAMINE RELEASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; ISOINDOLE DERIVATIVE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEDOCROMIL SODIUM; PENICILLAMINE; PHENAZINE DERIVATIVE; QUINAZOLINE DERIVATIVE; RETINOID; TACROLIMUS; THALIDOMIDE; URSODEOXYCHOLIC ACID;

GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPH NODE IRRADIATION; MORBIDITY; MORTALITY; PHOTOCHEMOTHERAPY; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY;

EID: 0034027251     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702235     Document Type: Review

References (91)

1. Ferrara JLM, Deeg HJ. Graft-versus-host disease. New Engl J Med 1991; 10: 667-674.
2. Storek J, Gooley T, Siadak M. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 1997; 12: 4705-4709.
3. Lucarelli G, Galimberti M, Polchi P et al. Bone marrow transplantation in patients with thalassemia. New Engl J Med 1990; 322: 417-421.
4. Gaziev D, Polchi P, Galimberti M et al. Graft-versus-host disease after bone marrow transplantation for thalassemia: an analysis of incidence and risk factors. Transplantation 1997; 6: 854-860.
5. Lazarus HM, Rowe JM. New and experimental therapies for treating graft-versus-host disease. Blood Rev 1995; 2: 117-133.
6. Beatty PG, Hansen JA, Longton GM et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies. Transplantation 1991; 2: 443-447.
7. Morton AJ, Anasetti C, Gooley T et al. Chronic graft-versus-host disease (GVHD) following unrelated donor transplantation. Blood 1997; 10 (Suppl. 1): 590a (Abstr. 2623).
8. Urbano-Ispizua A, Garcia-Conde J, Brunet S et al. High incidence of chronic graft versus host disease after allogeneic peripheral blood progenitor cell transplantation. Haematologica 1997; 82: 683-689.
9. Neiderwieser D, Pepe M, Storb R et al. Factors predicting chronic graft-versus-host disease and survival after marrow transplantation for aplastic anemia. Bone Marrow Transplant 1989; 4: 151-156.
10. Sullivan KM, Witherspoon RP, Storb R et al. Alternating-day cyclosporine and prednisone treatment of high-risk chronic graft-v-host disease. Blood 1988; 2: 555-561.
11. Wingard JR, Piantadosi S, Vogelsang GB et al. Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood 1989; 4: 1428-1435.
12. Schiller G, Gale RP. Is there an effective therapy for chronic graft-versus-host disease? Bone Marrow Transplant 1993; 11: 189-192.
13. Shulman HM, Sullivan KM, Weiden PL et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
14. Sullivan KM. Acute and chronic graft-versus-host disease in man. Int J Cell Cloning 1986; 4: 42-93.
15. Shulman HM, Sale GE, Lemer KG et al. Chronic cutaneous graft-versus-host disease in man. Am J Pathol 1978; 91: 545-570.
16. Weinberg K, Annet G, Kashyap A et al. The effect of thymic function on immunocompetence following bone marrow transplantation. Biol Blood Marrow Transplant 1995; 1: 18-25.
17. Crisi GM, Tsiagbe VK, Russo C et al. Evaluation of presence and functional activity of potentially self-reactive T cells in aged mice. Int Immunol 1995; 8: 387-395.
18. Parkman R. Chronic graft-versus-host disease. Curr Opin Hematol 1998; 5: 22-25.
19. Sullivan KM, Shulman HM, Storb R et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 2: 267-276.
20. Sullivan KM, Witherspoon RP, Storb P et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988; 2: 546-554.
21. Sullivan KM, Witherspoon RP, Storb R. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood 1988; 2: 555-561.
22. Sullivan KM, Mori M, Witherspoon R et al. Alternating-day cyclosporine and prednisolone (CSP/PRED) treatment of chronic graft-versus-host disease (GVHD): predictors of survival. Blood 1990: 76: 568a.
23. Sullivan KM, Goley T, Nims J et al. Comparison of cyclosporine (CSP), prednisone (PRED) or alternating-day CSP/PRED in patients with standard and high risk chronic graft-versus-host disease (GVHD). Blood 1993; 10 (Suppl. 1): 215a (Abstr. 845).
24. Sullivan KM, Flowers MED, Nims J et al. Results of four regimens of salvage treatment of refractory chronic graft-versus-host disease (GVHD). Blood 1996; 15 (Suppl. 1): 644a (Abstr. 2564).
25. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharm Ther 1968; 6: 303-306.
26. Keenan RJ, Eiras G, Burkart GJ et al. Immunosuppressive properties of thalidomide. Transplantation 1991; 52: 908-910.
27. Vogelsang GB, Hess AD, Brundette GR, Santos GW. Thalidomide induction of bone marrow transplantation tolerance. Transplant Proc 1987; 19: 2658-2661.
28. Moriera AL, Sampaio EP, Znuidzinas A et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993; 177: 1675-1680.
29. Vogelsang GB, Farmer ER, Hess AD et al. Thalidomide for the treatment of chronic graft-versus-host disease. New Engl J Med 1992; 16: 1055-1058.
30. Heney D, Norfolk DR. Wheldon J et al. Thalidomide treatment for chronic graft-versus-host disease. Br J Haematol 1991; 78: 23-27.
31. Rovelli A, Arrigo C, Nesi F et al. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation. Bone Marrow Transplant 1998; 21: 577-581.
32. Parker PM, Chao N, Nademanee A et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood 1995; 9: 3604-3609.
33. Eppinger T, Ehninger G, Steinert M et al. 8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease. Transplantation 1990; 50: 807-811.
34. Jampel RM, Farmer ER, Vogelsang GB et al. PUVA therapy for chronic cutaneous graft-versus-host disease. Arch Dermatol 1991; 127: 1673-1678.
35. Vogelsang GB, Wolff D, Altomonte V et al. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA). Bone Marrow Transplant 1996; 17: 1061-1067.
36. Lindelöf B et al. PUVA and cancer: a large-scale epidemiology study. Lancet 1991; 339: 91-93.
37. Altman JS, Adler SS. Development of multiple cutaneous squamous cell carcinomas during PUVA treatment for chronic graft-versus-host disease. J Am Acad Dermatol 1994; 31: 505-507.
38. Aubin F, Brion A, Deconinck E et al. Phototherapy in the treatment of cutaneous graft-versus-host disease. Transplantation 1995; 1: 151-155.
39. Atkinson K, Weller P, Rayman W, Biggs J. PUVA therapy for drug-resistant graft-versus-host disease. Bone Marrow Transplant 1986; 1: 227-236.
40. Volc-Platzer B, Hönigsmann H, Hinterberger W, Wolff K. Photochemotherapy improves chronic cutaneous graft-versus-host disease. J Am Acad Dermatol 1990; 23: 220-228.
41. Edelson R, Berger C, Gasparro F et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy: preliminary result. New Engl J Med 1987; 316: 297-303.
42. Wolfe JT, Lessin SR, Anjali HS et al. Review of immunomodulation by photopheresis: treatment of cutaneous T-cell lymphoma, autoimmune disease, and graft rejection. Artif Organs 1994; 18: 888-897.
43. Costanzo-Nordin MR, Hubbel EA, O'Sullivan EJ et al. Successful treatment of heart transplant rejection with photopheresis. Transplantation 1992; 53: 808-815.
44. Gerber M, Gmeinhart B, Volc-Platzer B et al. Complete remission of lichen-planus-like graft-versus-host disease (GVHD) with extracorporeal photochemotherapy (ECP). Bone Marrow Transplant 1997; 19: 517-519.
45. Owsianowski M, Gollnick H, Siegret W et al. Successful treatment of chronic graft-versus-host disease with extracorporeal photopheresis. Bone Marrow Transplant 1994; 14: 845-848.
46. Rosetti F, Zulian F, Dall'Amico R et al. Extracorporeal photopheresis as single therapy for extensive, cutaneous, chronic graft-versus-host disease. Transplantation 1995; 59: 149-151.
47. Perez M, Edelson R, Laroche L, Berger C. Inhibition of anti-skin allograft immunity by infusions with syngeneic photoinactivated effector lymphocytes. J Invest Dermatol 1989; 92: 669-676.
48. Besnier DP, Chabannes D. Mahè B et al. Treatment of graft-versus-host disease by extracorporeal photochemotherapy. Transplantation 1997, 1: 49-54.
49. Dall'Amico R, Rossetti F, Zulian F et al. Photopheresis in paediatric patients with drug-resistant chronic graft-versus-host disease. Br J Haematol 1997; 97: 848-854.
50. Rabitsch W, Reiter E, Keil F et al. Extracorporeal photopheresis (ECP) in extensive chronic graft-versus-host disease (GVHD). Blood 1997; 10 (Suppl. 1): 376a (Abstr. 1676).
51. Sniecinski I, Parker P, Dagis A et al. Extracorporeal photopheresis (EP) is effective treatment for chronic refractory graft-versus-host disease (GvHD). Blood 1998; 10 (Suppl. 1): 454a (Abstr. 1877).
52. Hooks MA. Tacrolimus, a new immunosuppressant - review of the literature. Ann Pharmacol 1994; 28: 501-511.
53. Przepiorka D, Ippoliti C, Khouri I et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation. Blood 1996; 11: 4383-4389.
54. Koehler MT, Howrie D, Mirro J et al. FK506 (tacrolimus) in the treatment of steroid-resistant acute graft-versus-host disease in children undergoing bone marrow transplantation. Bone Marrow Transplant 1995; 15: 895-899.
55. Tzakis AG, Abu-Elmagd K, Fung JJ et al. FK506 rescue in chronic graft-versus-host disease after bone marrow transplantation. Transplant Proc 1991; 23: 3225-3227.
56. Kanamaru A. Takemoto Y, Kakishita E et al. FK 506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporin and/or other immunosuppressants. Bone Marrow Transplant 1995; 15: 885-889.
57. Slavin S, Reitz B, Bieber CP et al. Transplantation tolerance in adult rats using total lymphoid irradiation: permanent survival of skin, heart, and marrow allografts. J Exp Med 1978; 147: 700-707.
58. Strober S, Tanay A, Field E et al. Efficacy of total lymphoid irradiation in intractable rheumatoid arthritis. Ann Intern Med 1985; 102: 441-449.
59. Socie G, Devergie A, Cosset JM et al. Low-dose (one Gray) total lymphoid irradiation for extensive, drug-resistant chronic graft-versus-host disease. Transplantation 1990; 3: 657-658.
60. Bullorsky EO, Shakley CM, Stemmelin GR et al. Total lymphoid irradiation for treatment of drug resistant chronic GVHD. Bone Marrow Transplant 1993; 11: 75-76.
61. Fung HC, Voss NJ, Barnet MJ et al. Low dose thoracoabdominal irradiation for treatment of advanced chronic graft-versus-host disease. Blood 1995: 10 (Suppl. 1): 390a (Abstr. 1550).
62. Devergie A, Grinski T, Sociè G, Gluckman E. Immunosuppressive treatment with lGy lymphoid irradiation for treatment of severe chronic graft-versus-host disease. Blood 1996; 10 (Suppl. 1): 644a (Abstr. 2565).
63. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225-243.
64. Basara N, Blau WI, Romer E et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant 1998; 22: 61-65.
65. Nash RA, Fulong T, Storb R et al. Mycophenolate mofetil (MMF) as salvage treatment for graft-versus-host disease (GVHD) after allogeneic hematopoietic transplantation (HSCT): safety analysis. Blood 1997; 10 (Suppl. 1): 105a (Abstr. 459).
66. Mookerjee B, Altomonte V, Vogelsang G. Salvage therapy with mycophenolate mofetil and FK506 for refractory chronic graft-versus-host disease. Blood 1998; 10 (Suppl. 1): 457a (Abstr. 559).
67. Holdines MR. Clinical pharmacokinetics of clofazimine. A review. Clin Pharmacol 1989; 16: 74-83.
68. Mackey JP, Barnes J. Clofazimine in the treatment of discoid lupus erythematosus. Br J Dermatol 1974; 91: 93-96.
69. Lee S, Wegner SA, McGarigle CJ et al. Treatment of chronic graft-versus-host disease with clofazimine. Blood 1997; 7: 2298-2302.
70. Geiger J, Saurat J. Acitretin and etretinate. How and when they should be used. Dermatol Clin 1993; 121: 367-372.
71. Marcellus DC, Altomonte VL, Farmer ER et al. Etretinate therapy for refractory sclerodermatous chronic graft-versus-host disease. Blond 1999; 1: 66-70.
72. Leuchner U, Fischer H. Kurtz W et al. Ursodeoxycholic acid in primary cirrhosis: results of a controlled, double-blind trial. Gastroenterology 1989; 97: 1268-1274.
73. Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for treatment of primary cirrhosis. New Engl J Med 1991; 324: 1548-1554.
74. Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1990; 11: 12-15.
75. Fried RH, Murakami CS, Fisher LD et al. Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. Ann Intern Med 1992; 116: 624-629.
76. Summerfield GP, Bellingam AJ, Bunch C, Woodrow JC. Successful treatment of chronic cutaneous graft-versus-host-disease (GVHD) with penicillamine. Clin Lab Haemat 1983; 5: 313-318.
77. Lönnqvist B, Carneskog J. Cyclophenile in 9 cases of severe sclerotic chGVHD of the skin. Bone Marrow Transplant 1998; 21 (Suppl. 1): S112 (Abstr. 387).
78. Levi-Schatfer F, Nagler A, Slavin S et al. Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: effect of haloginone. J Invest Dermatol 1996; 106: 84-88.
79. Claman HN, Lee Choi K, Sujansky W, Vatter AE. Mast cell 'disappearance' in chronic murine graft-versus-host disease (GVHD) - ultrastructural demonstration of 'phantom' mast cells. J Immunol 1986; 137: 2009-2013.
80. Levi-Schaffer F, Goldenhersh MA, Segal V, Nagler A. Nedocromil sodium ameliorates skin manifestations in a murine model of chronic graft-versus-host disease. Bone Marrow Transplant 1997; 19: 823-828.
81. Sullivan KM, Mori M, Sanders J et al. Late complications of allogeneic and autologous marrow transplantation. Bone Marrow Transplant 1992; 10 (Suppl. 1): 127-134.
82. Meyers JD. Infection in bone marrow transplant recipients. Am J Med 1986; 81: 27-38.
83. Lum LG. The kinetics of immune reconstitution after human marrow transplant. Blood 1987; 69: 369-380.
84. Kahls P, Panzer S, Kletter K et al. Functional asplenia after bone marrow transplantation: a late complication related to extensive chronic graft versus host disease. Ann Intern Med 1988; 109: 461-464.
85. Rege K, Mehta J, Treleaven J et al. Fatal pneumococcal infections following allogeneic bone marrow transplantation. Bone Marrow Transplant 1994; 14: 903-906.
86. Singhul S, Mehta J. Reimmunization after blood or marrow stem cell transplantation. Bone Marrow Transplant 1999; 23: 637-646.
87. Storb R, Deeg JH, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. New Engl J Med 1986; 314: 729-735.
88. Chao NJ, Schmidt GM, Niland JC et al. Cyclosporin, methotrexate, and prednisone compared with cyclosporin and prednisone for prophylaxis of acute graft-versus-host disease. New Engl J Med 1993; 329: 1225-1230.
89. Lönnqvist B, Aschan J, Ljugman P, Ringdèn O. Long-term cyclosporine therapy may decrease the risk of chronic graft-versus-host disease. Br J Haematol 1990; 4: 547-548.
90. Tiberghien P. 'Suicide' gene for the control of graft-versus-host disease. Curr Opin Hematol 1998; 5: 478-482.
91. Bonini C, Ferrari G. Verzeletti S et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997; 276: 1719-1724.